Sionna Therapeutics Revenue and Competitors

Boston, MA USA

Location

#2284

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Sionna Therapeutics's estimated annual revenue is currently $2.9M per year.(i)
  • Sionna Therapeutics's estimated revenue per employee is $62,660
  • Sionna Therapeutics's total funding is $332M.

Employee Data

  • Sionna Therapeutics has 47 Employees.(i)
  • Sionna Therapeutics grew their employee count by 38% last year.

Sionna Therapeutics's People

NameTitleEmail/Phone
1
Manager Executive Office EA to President & CEOReveal Email/Phone
2
Co-founder and SVP Head ResearchReveal Email/Phone
3
Co-founder and VP Medicinal Chemistry at Sionna TherapeuticsReveal Email/Phone
4
President and CEOReveal Email/Phone
5
Co-Founder and VP, Medicinal ChemistryReveal Email/Phone
6
Manager Executive Office EA to President & CEOReveal Email/Phone
7
Chief Scientific OfficerReveal Email/Phone
8
Chief People OfficerReveal Email/Phone
9
Chief Financial Officer & Head Corporate DevelopmentReveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
N/A1110%N/AN/A
#10
$5.4M353%N/AN/A
Add Company

What Is Sionna Therapeutics?

We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.

keywords:N/A

$332M

Total Funding

47

Number of Employees

$2.9M

Revenue (est)

38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M47-4%N/A
#2
$5.5M47N/AN/A
#3
$7.1M47-10%N/A
#4
$7.2M47-11%$15M
#5
$5.5M477%N/A